Hemostasis Today

July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
Jul 30, 2026, 14:22

Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease

Stéphanie Forté, Principal Researcher at the Innovation Hub at the CHUM Research Center (CRCHUM), shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in British Journal of Haematology, adding:

”Our Quebec study on hydroxyurea in SC disease (HbSC) has just been the subject of an editorial commentary in the British Journal of Haematology.

The message of the commentary is clear: HbSC disease is not a ‘mild’ form of sickle cell disease — it is a biologically distinct entity, long understudied and undertreated out of an abundance of caution.

Our results show a 56 percent reduction in vaso-occlusive crises with hydroxyurea initiation, without complications related to hyperviscosity — a historical fear in this population.

Interestingly, treatment discontinuations were mostly related to modifiable barriers (prescription renewal, education, follow-up) rather than toxicity.

A reminder that patient support is as important as pharmacology.”

Title: Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec

Authors: Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent-Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté

Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease

Stay updated on all scientific advances with Hemostasis Today.